Prescribing Patterns Associated With Biologic Therapies for Psoriasis from a United States Medical Records Database

August 2019 | Volume 18 | Issue 8 | Original Article | 745 | Copyright © August 2019


Megan H. Noe MD MPH MSCE, Daniel B. Shin PhD, Jalpa A. Doshi PhD, David J. Margolis MD PhD, Joel M. Gelfand MD MSCE

University of Pennsylvania Perelman School of Medicine, Philadelphia, PA

Pfizer, Sanofi, Kerecis, and Cell Constructs. None of these activities are associated with the outcomes of this study. Joel Gelfand served as a consultant for BMS, Boehringer Ingelheim, GSK, Janssen Biologics, Novartis Corp, UCB (DSMB), Sanofi, and Pfizer Inc., receiving honoraria; and receives research grants (to the Trustees of the University of Pennsylvania) from Abbvie, Janssen, Novartis Corp, Celgene, Ortho Dermatologics, and Pfizer Inc.; and received payment for continuing medical education work related to psoriasis that was supported indirectly by Lilly, Ortho Dermatologic and Novartis. Funding: This study was supported by a research grant from Ortho-Dermatologics to the Trustees of the University of Pennsylvania. Ortho-Dermatologics and its associates did not participate in any aspects of the design, data collection, analysis, interpretation, or presentation of this study. Associates from Ortho-Dermatologics did have an opportunity to review a draft of this manuscript prior to journal submission.

REFERENCES

  1. Doshi JA, Takeshita J, Pinto L, et al. Biologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare population. J Am Acad Dermatol. 2016;74(6):1057-1065.e1054.
  2. Takeshita J, Gelfand JM, Li P, et al. Psoriasis in the US Medicare Population: Prevalence, Treatment, and Factors Associated with Biologic Use. J Invest Dermatol. 2015;135(12):2955-2963.
  3. Menter A, Papp KA, Gooderham M, et al. Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Eur Acad Dermatol Venereol. 2016;30(7):1148-1158.
  4. Bonafede M, Johnson BH, Fox KM, Watson C, Gandra SR. Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world setting. J Dermatolog Treat. 2013;24(5):369-373.
  5. Dommasch ED, Lee MP, Joyce CJ, Garry EM, Gagne JJ. Drug utilization patterns and adherence in patients on systemic medications for the treatment of psoriasis: A retrospective, comparative cohort study. J Am Acad Dermatol. 2018;79(6):1061-1068 e1061. 
  6. Chambers JD, Pope EF, Wilkinson CL, Neumann PJ. Discrepancies Between FDA-Required Labeling and Evidence that Payers Cite in Drug Coverage Policies. J Manag Care Spec Pharm. 2018;24(12):1240-+.
  7. Doshi JA, Li P, Ladage VP, Pettit AR, Taylor EA. Impact of cost sharing on specialty drug utilization and outcomes: a review of the evidence and future directions. Am J Manag Care. 2016;22(3):188-197.
  8. Nast A, Boehncke WH, Mrowietz U, et al. S3 - Guidelines on the treatment of psoriasis vulgaris (English version). Update. J Dtsch Dermatol Ges. 2012;10 Suppl 2:S1-95.
  9. Smith CH, Jabbar-Lopez ZK, Yiu ZZ, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. Br J Dermatol. 2017;177(3):628-636.
  10. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029-1072.
  11. Busard CI, Cohen AD, Wolf P, et al. Biologics combined with conventional systemic agents or phototherapy for the treatment of psoriasis: real-life data from PSONET registries. J Eur Acad Dermatol Venereol. 2018;32(2):245-253. 
  12. Shalom G, Cohen AD, Ziv M, et al. Biologic drug survival in Israeli psoriasis patients. J Am Acad Dermatol. 2017;76(4):662-669.e661.
  13. Armstrong AW, Bagel J, Van Voorhees AS, Robertson AD, Yamauchi PS. Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation. JAMA Dermatol. 2015;151(4):432-438.
  14. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009;60(4):643-659.
  15. Korber A, Thaci D, von Kiedrowski R, et al. Secukinumab treatment of moderate moderate to severe plaque psoriasis in routine clinical care: real-life data of prior and concomitant use of psoriasis treatments from the PROSPECT study. J Eur Acad Dermatol Venereol. 2018;32(3):411-419.

AUTHOR CORRESPONDENCE

Megan H. Noe MD MPH MSCE mnoe2@bwh.harvard.edu
Close Menu